Document is current

Article History

Received: 7 February 2022

Accepted: 7 December 2022

First Online: 20 December 2022

Declarations

:

: This project was approved by both the scientific and ethics committees of the Montreal Heart Institute (Quebec, Canada) on May 14th, 2020 (#2021–2787). All methods were performed in accordance with the relevant guidelines and regulations and as per the approved protocol. Informed consent was obtained from all subjects of this study.

: Not applicable.

: Dr. Tardif reports grant from Amarin, grants and personal fees from AstraZeneca, grant from Ceapro, grants, personal fees and minor equity interest from Dalcor, grants from Esperion, personal fees from HLS Therapeutics, grants from Ionis, grants from Novartis, personal fees from Pendopharm, grants from Pfizer, outside the submitted work; in addition, Dr. Tardif has a patent Genetic marker for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent pending, and a patent Methods for using low dose colchicine after myocardial infarction pending (Dr. Tardif has waived his rights in colchicine patents).Dr. Ducharme receives salary support from the Fonds de recherche du Québec—Santé. He has received research contracts from Ionis Pharmaceuticals, Biogen, Wave Life Sciences, AZTherapies and Janssen Pharmaceuticals. Dr. Ducharme has received payments for advisory boards and/or speaker fees from Eisai, Biogen, Sunovion, Innodem Neurosciences, HealthTech Connex and QurAlis. He is the co-owner of AFX Medical Inc. There is no direct relationship between those interests and the work in this article.Dr. Vadeboncoeur participates in a study (RAFF4) granted by Cipher.Other authors report no conflict of interest.